Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MnG4R5l1d3SxeHnjJGF{e2G7 NUL6W2Z2PzJiaB?= M2TrTmROW09? NEfSbZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGW6cILld5NqdmdiUFmzT4FteGijIFW1OFVMKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFAyPThizszN MX6yOFkxODJ4Nh?=
DU145 MnnUR5l1d3SxeHnjJGF{e2G7 Mn7BO|IhcA>? NF7V[VZFVVOR MnHSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MUGyOFkxODJ4Nh?=
A2780 M4HI[mN6fG:2b4jpZ{BCe3OjeR?= NIHGcFY4OiCq MlPUSG1UVw>? NXXTXlZ5S3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=> MXKyOFkxODJ4Nh?=
U87MG NWXNbpZNS3m2b4TvfIlkKEG|c3H5 NELyVYg4OiCq MmXTSG1UVw>? MlGzR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= NVn4OJFJOjR7MECyOlY>
A2780 NGPv[GlHfW6ldHnvckBCe3OjeR?= MlroNUBp MnjJSG1UVw>? MVvJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? NUHYOVdPOjR7MECyOlY>
DU145 MX\GeY5kfGmxbjDBd5NigQ>? M3q0TFEhcA>? NIfnTZBFVVOR MkDTTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? MVmyOFkxODJ4Nh?=
A2780 M1vCWWZ2dmO2aX;uJGF{e2G7 MX6xJIg> M1\JWmROW09? M1;kb2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP M1\mO|I1QTByMk[2
MCF7 Mk\LSpVv[3Srb36gRZN{[Xl? NInsNIcyKGh? M1H6T2ROW09? M17OZ2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? NWC3e|AzOjR7MECyOlY>
U87MG M3fCVmZ2dmO2aX;uJGF{e2G7 MoDuNUBp NVT6VlRrTE2VTx?= M37BWmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1? NF\1cVMzPDlyMEK2Oi=>
A2780 NHfScohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ZZVg4OiCq Mo\3SG1UVw>? MVnFR|UxRTBwNUKg{txO Mor4NlQ6ODB{Nk[=
SKMES-1 NWGyd3V{S3m2b4TvfIlkKEG|c3H5 NWLqTG1DOSEQvF2= NGjxS4E4OiCq NV\H[VF[UW6mdXPld{Bk\WyuIHTlZZRp NEfpUIUzPjBzM{OxPC=>
H596 MnK1SpVv[3Srb36gRZN{[Xl? M2\x[|Eh|ryP MXPJcZBicXK|IHPlcIwhdWmpcnH0bY9v NVXoSoV2OjZyMUOzNVg>
HCC2450 MWTGeY5kfGmxbjDBd5NigQ>? MYSxJO69VQ>? MkK2TY1x[Wm{czDj[YxtKGmwdnHzbY9v MX6yOlAyOzNzOB?=
A549 NVfnfo5DTnWwY4Tpc44hSXO|YYm= MorSOVAxKG6P MUe0PEBp NXnRXlNMTE2VTx?= MXrJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? NYTVd49nOjV7M{eyPVk>
A549 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxJO69VQ>? NGrGOW84OiCq MUDEUXNQ MmLNTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3;TWVI2QTN5Mkm5
H522 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\WWVJMOSEQvF2= NVvuT4JSPzJiaB?= NGPiWmFFVVOR MULJcohq[mm2czDj[YxtKGe{b4f0bC=> NYHPdVRUOjV7M{eyPVk>
LNCaP M17zXWZ2dmO2aX;uJGF{e2G7 MWOxJO69VQ>? M4fySXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| MkHBNlU{PjB5OUm=
LNCaP95 MX3GeY5kfGmxbjDBd5NigQ>? MYmxJO69VQ>? M4nld3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NXjFWVZPOjV|NkC3PVk>
HCT-15 NUXpc5FWSXCxdH;zbZMhSXO|YYm= MYCxNEDPxE1? MYO0PEBp MWLEUXNQ MlPrTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MWGyOVE2OjJ2NR?=
HCT-116 M4TsfmFxd3Sxc3nzJGF{e2G7 MnO1NVAh|ryP MlPwOFghcA>? MlnmSG1UVw>? M3jUS2lv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NEXhZmszPTF3MkK0OS=>
NCI-H460 M3Pid2Fxd3Sxc3nzJGF{e2G7 M4\mZVExKM7:TR?= NGPKV2k1QCCq NV7JV4dPTE2VTx?= M3TuSWlv\HWlZYOgZZBweHSxc3nzJIlvKE6FST3IOFYxKGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= NWTWdYlyOjVzNUKyOFU>
SKOV-3 MlGxRZBwfG:|aYOgRZN{[Xl? NV6zXJg{OTBizszN NWXtSHo6PDhiaB?= NGD0cWhFVVOR NFG0V3BKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MYqyOVE2OjJ2NR?=
BSY-1 NUTyUGpWSXCxdH;zbZMhSXO|YYm= NWG0ZpZ4OTBizszN M4P1Z|Q5KGh? NEm3bJlFVVOR NVWzepRGUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M4T2T|I2OTV{MkS1
MKN-1 NFKwO5ZCeG:2b4Ppd{BCe3OjeR?= NWTwW5htOTBizszN M3vwNFQ5KGh? Ml:zSG1UVw>? NXT5eVlmUW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MmnzNlUyPTJ{NEW=
NCI-H522 Ml3KRZBwfG:|aYOgRZN{[Xl? MlHFNVAh|ryP MlPOOFghcA>? MmDDSG1UVw>? NXribm1qUW6mdXPld{BieG:ydH;zbZM> NF32WZozPTF3MkK0OS=>
OVCAR-3 MmPmRZBwfG:|aYOgRZN{[Xl? MnzyNVAh|ryP NXH6VFc1PDhiaB?= NUPOOotoTE2VTx?= MmryTY5lfWOnczDhdI9xfG:|aYO= NEjWXIszPTF3MkK0OS=>
HBC-5 MUnBdI91d3OrczDBd5NigQ>? MoP5NVAh|ryP MnjHOFghcA>? Mn75SG1UVw>? MWLJcoR2[2W|IHHwc5B1d3Orcx?= MXGyOVE2OjJ2NR?=
RXF-631L M{CyNGFxd3Sxc3nzJGF{e2G7 NHPhRWIyOCEQvF2= NFnMToc1QCCq MVLEUXNQ MXTJcoR2[2W|IHHwc5B1d3Orcx?= NHuwTGgzPTF3MkK0OS=>
MKN-45 M{fJZWFxd3Sxc3nzJGF{e2G7 NWnXTmNyOTBizszN Ml3KOFghcA>? NIeyRldFVVOR NYq2Nm9pUW6mdXPld{BieG:ydH;zbZM> M1;uWlI2OTV{MkS1
BON-1 NGK0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjHV4g2ODBibl2= Mnv0NVAh\A>? NIrYWG9FVVOR M4j0c2lvcGmkaYTzJINmdGxiZ4Lve5Rp M33WRlI2ODJ4Mkmy
BON-1 NIHzeXlHfW6ldHnvckBCe3OjeR?= NXfSUHlsPTByIH7N NXG1SXlQPCCq NGOx[HVFVVOR NWnRNlVlUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> M{TSdlI2ODJ4Mkmy
QGP-1 NE\EVIJHfW6ldHnvckBCe3OjeR?= NXm5TWR[PTByIH7N Mn:xOEBp NYXXV5JxTE2VTx?= NInzNmpKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez MmrDNlUxOjZ{OUK=
Huh7 MmLoSpVv[3Srb36gRZN{[Xl? MorLNUDPxE1? NXH2XngzOSCq MUfEUXNQ NG\NTVlKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHNmejR5NB?= NVTtfpR7OjVyMES0NFM>
BNL NVGybYFrTnWwY4Tpc44hSXO|YYm= M370RVEh|ryP Ml\TNUBp MULEUXNQ M4Tt[GlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? NFXmSXgzPTByNESwNy=>
MDA-MB-175 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr0T5UyKM7:TR?= MYm1JIQ> M1ToVWROW09? Mni1TWM2ODxzIN88US=> NXnx[ZZtOjR6N{m3PVY>
MDA-MB-134 NGGz[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSzd3VuOSEQvF2= NVjoZWVLPSCm NUfhPIZqTE2VTx?= NF3ZSXFKSzVyPEGg{txO NIXBVW4zPDh5OUe5Oi=>
HCC1500 NY[zclVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvQNUDPxE1? NUDLfoZDPSCm M2Dnb2ROW09? MkjTTWM2ODxzIN88US=> MV6yOFg4QTd7Nh?=
EFM-19 M4rU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDrSnJtOSEQvF2= M1jZelUh\A>? NGr2cINFVVOR Mn3UTWM2ODxzIN88US=> MlHENlQ5Pzl5OU[=
ZR-75-30 M2jVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITLS5UyKM7:TR?= NGW1OGk2KGR? MmnVSG1UVw>? MnnvTWM2ODxzIN88US=> M3H6PFI1QDd7N{m2
MDA-MB-361 NIrDVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TBVVEh|ryP MUW1JIQ> M37JZWROW09? NIPqR2dKSzVyPEGg{txO MVGyOFg4QTd7Nh?=
T-47D NFfFbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfae3cyKM7:TR?= M1y5c|Uh\A>? MonkSG1UVw>? MofwTWM2ODxzIN88US=> M3TkeVI1QDd7N{m2
SK-BR-3 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoThNUDPxE1? MVS1JIQ> MnjKSG1UVw>? MXrJR|UxRDFizszN NEj0e3kzPDh5OUe5Oi=>
UACC-732 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK2NUDPxE1? NW[2SoZ2PSCm Ml3VSG1UVw>? M1PQeWlEPTB:MTFOwG0> MljoNlQ5Pzl5OU[=
BT-474 NE\WflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xJO69VQ>? Mom4OUBl Mm\RSG1UVw>? NIXRNlRKSzVyPEGg{txO MX6yOFg4QTd7Nh?=
HCC202 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P4PVEh|ryP MnHsOUBl M{X6fGROW09? MoPlTWM2ODxzIN88US=> NWHGOoR1OjR6N{m3PVY>
MCF7 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGxJO69VQ>? NHHSfpU2KGR? MUXEUXNQ M1ri[WlEPTB:MTFOwG0> NWfNWlgzOjR6N{m3PVY>
MDA-MB-415 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWixJO69VQ>? Mnf2OUBl NETERllFVVOR MXvJR|UxRDFizszN MYiyOFg4QTd7Nh?=
MDA-MB-453 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxJO69VQ>? M2i3TFUh\A>? MY\EUXNQ MX3JR|UxRDFizszN M{nlZ|I1QDd7N{m2
ZR-75-1 NYj1bIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\WVndLOSEQvF2= NVrNdYJmPSCm MX3EUXNQ NEHJWFZKSzVyPEGg{txO M37a[VI1QDd7N{m2
HCC38 M{LQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrsNndCOSEQvF2= NHXsN4U2KGR? M2HjXWROW09? MV\JR|UxRDFizszN M{X3OFI1QDd7N{m2
HCC1419 M17pWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOyb2U5OSEQvF2= NYXHbotjPSCm M{jEUmROW09? MYjJR|UxRDFizszN NH71PJczPDh5OUe5Oi=>
UACC-812 M{LjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxJO69VQ>? MoDVOUBl M4jhUWROW09? NHT0cmRKSzVyPEGg{txO Mly1NlQ5Pzl5OU[=
HCC1187 NFLJ[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2naTVEh|ryP NVLBbI5GPSCm NFO5ZmVFVVOR Ml\UTWM2ODxzIN88US=> NWnPPXBNOjR6N{m3PVY>
KPL-1 NGXG[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0NUDPxE1? NX3KU3hNPSCm NXLEdZRmTE2VTx?= NHTrcHBKSzVyPEGg{txO NWDjcoZoOjR6N{m3PVY>
SUM-225 M1H2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1RnNmOSEQvF2= NWfsNpM2PSCm Mm[0SG1UVw>? NXvwR2xlUUN3MEyxJO69VQ>? NWP5SYhwOjR6N{m3PVY>
EFM-192A M3jKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULUS4dpOSEQvF2= M1jZR|Uh\A>? MXrEUXNQ M3ewTmlEPTB:MTFOwG0> Mn7QNlQ5Pzl5OU[=
JIMT-1 NHXtXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxJO69VQ>? NWTNSWJmPSCm MWHEUXNQ MX7JR|UxRDFizszN M2jkNFI1QDd7N{m2
HCC1143 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH5NYYyKM7:TR?= M2nY[VUh\A>? M36xUmROW09? Mmf5TWM2ODxzIN88US=> M17nUFI1QDd7N{m2
HCC2218 M4KzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fwRVEh|ryP MXi1JIQ> M37GRWROW09? Mk\wTWM2ODxzIN88US=> M1rVVVI1QDd7N{m2
MDA-MB-468 M1\rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nvelEh|ryP NG\3dIg2KGR? NGXabFJFVVOR MmG2TWM2ODxzIN88US=> MYqyOFg4QTd7Nh?=
BT-20 NUDWNJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPINUDPxE1? NV7RNZVrPSCm M1K2UmROW09? MkHnTWM2ODxzIN88US=> NFjRTpAzPDh5OUe5Oi=>
MDA-MB-435 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPIS2c4OSEQvF2= NFHoW4k2KGR? M1zxT2ROW09? M4PBfGlEPTB:MTFOwG0> M3PqOFI1QDd7N{m2
BT-549 NEXT[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxJO69VQ>? M{LN[lUh\A>? NF\Te2ZFVVOR M4fGRmlEPTB:MTFOwG0> NGfuXnozPDh5OUe5Oi=>
HCC1806 M3jPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWixJO69VQ>? NEHROYI2KGR? NGPKcXFFVVOR MX;JR|UxRDFizszN M4nIR|I1QDd7N{m2
HCC1937 NYXOSWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T6NVEh|ryP NH:zelk2KGR? M3L0dWROW09? M2L4UmlEPTB:MTFOwG0> NHXXT2YzPDh5OUe5Oi=>
Hs578T Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zVlAyKM7:TR?= M17UZlUh\A>? NEDNRWVFVVOR NXrHWmtqUUN3MEyxJO69VQ>? NYjtN4tkOjR6N{m3PVY>
LN18 NYHPfIllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHWNlAh|ryP NX;4U5NkPzJiaB?= M3vseWROW09? MkfJTWM2ODx3IN88US=> MWqyOFc1OTB5NB?=
LN229 NVvyO4tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWxVZYzOCEQvF2= MWi3NkBp NVvNTYxPTE2VTx?= NGjmSGlKSzVyPEWg{txO NX31T29QOjR5NEGwO|Q>
LNZ308 NIDaS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnDZpIzOCEQvF2= M2n5W|czKGh? NULuPVdjTE2VTx?= NHXXbHVKSzVyPEWg{txO NWPsWIdKOjR5NEGwO|Q>
T98G NHzyUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUeyNEDPxE1? NYPad4l2PzJiaB?= MmXnSG1UVw>? NIfrcVVKSzVyPEWg{txO M3rpXlI1PzRzMEe0
U87 NUPuTWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVeyNEDPxE1? NX\lUJNKPzJiaB?= M2jLT2ROW09? M17uPGlEPTB:NTFOwG0> Mn;SNlQ4PDFyN{S=
LN18 NHXOW5JHfW6ldHnvckBCe3OjeR?= MlH1OUDPxE1? MmT1NlQhcA>? Ml\tSG1UVw>? MmL1TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NGLxN3MzPDd2MUC3OC=>
LNZ308 MYXGeY5kfGmxbjDBd5NigQ>? MW[1JO69VQ>? NGOxWnEzPCCq NEnYOpBFVVOR MnvJTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MnvnNlQ4PDFyN{S=
Saos-2 M3eyVmZ2dmO2aX;uJGF{e2G7 Mmn5OVAh|ryP MWS0PEBp MlzBTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MkPSNlQ4Ojd4NkC=
MG-63 MVLGeY5kfGmxbjDBd5NigQ>? MXG1NEDPxE1? MYG0PEBp MUXJcohq[mm2czDj[YxtKGmwdnHzbY9v MViyOFczPzZ4MB?=
SJSA-1 M4PJZ2Z2dmO2aX;uJGF{e2G7 MX21NEDPxE1? M1vTN|Q5KGh? M{LKeGlvcGmkaYTzJINmdGxiaX72ZZNqd25? MnTrNlQ4Ojd4NkC=
Saos-2 Mnu1SpVv[3Srb36gRZN{[Xl? Mk\tOVAh|ryP NUjrem14PDhiaB?= MX7Jcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u M4fkXFI1PzJ5Nk[w
MG-63 M4jFWWZ2dmO2aX;uJGF{e2G7 MoPhOVAh|ryP MoTOOFghcA>? NHHWeJhKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v M3HjWVI1PzJ5Nk[w
SJSA-1 M{exPGZ2dmO2aX;uJGF{e2G7 M2r0clUxKM7:TR?= MYK0PEBp NX3DNmJTUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MmHENlQ4Ojd4NkC=
Saos-2 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PTN|UxKM7:TR?= NHm3Xoo1QCCq NUDCPIRjUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M2nxfFI1PzJ5Nk[w
MG-63 NX[1cmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj2U2s2OCEQvF2= NGe3d2U1QCCq NFHWOGZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MoThNlQ4Ojd4NkC=
SJSA-1 NEfiT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfjXYJ[PTBizszN M1ntVFQ5KGh? NVLDTVhEUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M{n0VVI1PzJ5Nk[w
FaDu MmX4SpVv[3Srb36gRZN{[Xl? NGXFRok2KM7:TR?= Mn3oNlQhcA>? NYfE[mxETE2VTx?= NVLiW2IyWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NGDXWG8zPDZ|MUG0Oy=>
EMT6 Moj1SpVv[3Srb36gRZN{[Xl? M2TGZlUh|ryP MUeyOEBp NYWwZZpkTE2VTx?= M1;icXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NXjJNXdSOjR4M{GxOFc>
HCT116 NFGyPYNHfW6ldHnvckBCe3OjeR?= NVvSPGszPSEQvF2= NUP1VpBjOjRiaB?= MWTEUXNQ MXjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= M1jjRlI1PjNzMUS3
U87 Mn[2SpVv[3Srb36gRZN{[Xl? MojiOUDPxE1? MnvqNlQhcA>? NEDwXpZFVVOR MnTlVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MoWzNlQ3OzFzNEe=
GBM NHSzZ3hCeG:ydH;zbZMhSXO|YYm= Mn7PNu69VQ>? M3e5VlQ5cA>? NIraN5lFVVOR MXLpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 MU[yOFUxODR7Mh?=
BON NVG1[|Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDPflYyNTYQvF2= MX63Nog> M17k[IRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> MmqwNlQ1PDN3MkO=
BON M3PQ[2Fxd3C2b4Ppd{BCe3OjeR?= NXLZO3MzOS13zszN MkfVNlRp MWrpcoNz\WG|ZYOgZZBweHSxc3nz MlroNlQ1PDN3MkO=
H1975 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLrNE4{NTlwNt88US=> NEXtNpg4Omh? MYXEUXNQ NUjOVm13UUN3ME2xMlM5Pc7:TR?= MmDWNlQ{Ozd6NE[=
H1975 M2\PdGFxd3C2b4Ppd{BCe3OjeR?= M3\BUlLPxE1? M{\BNVI1cA>? M2jPUWROW09? M3TtU4lv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 Mmj6NlQ{Ozd6NE[=
T-ALL MVPBdI9xfG:|aYOgRZN{[Xl? NUG3fHlj[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NFG2[JQzPCCxcjC0PIg> NXL5dIx1TE2VTx?= MVjh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= NGPuWIIzPDNzMEezOi=>
BCR-ABL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTaNE4zPS1zMN88US=> NHOzOFI1\A>? NWPVV5Jbe2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?= MkiyNlQzPDR4MUK=
LC-1/SQSF MUjGeY5kfGmxbjDBd5NigQ>? NVvkVWwzO87:TR?= MnyxNlRp MnS2SG1UVw>? NYi3[|ZU\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt NFj5ZWszOzl6MEC5Ny=>
Primary CLL cells M3z2O2Fxd3C2b4Ppd{BCe3OjeR?= Mn\yNU0yOM7:TR?= M3fHXFQ5cA>? NInucItqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{ NVnKV3o1OjN6NUC4NFc>
Primary CLL cells MYfLbY5ie2ViQYPzZZk> MWKy{txO NIDkRYI{OG2rbh?= Mlvi[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? MXiyN|g2ODhyNx?=
Primary CLL cells MX\DfZRwfG:6aXOgRZN{[Xl? M4nET|LPxE1? MX:yOIg> MYnpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 NGDyXYgzOzh3MEiwOy=>
human NSCLC cell lines MVPBdI9xfG:|aYOgRZN{[Xl? MWmwMlEzPS12zszN MnvxNlRp NHr6c3pFVVOR M3SzOWlEPTC|IILhcodmeyCocn;tJFAvPC1{zszN M3\CO|I{PTZ{NEey
human HCC cell lines NGjxfZpE\WyuII\pZYJqdGm2eTDhd5NigQ>? NYHiWGdZOC5yMEWtNe69VQ>? NGPyR3g1QGh? MknMTWM2OD1zzszN NYfl[lRyOjN2OEm5PVk>
Huh7 NIPab2JMcW6jc3WgRZN{[Xl? NUf4bYhkOc7:TR?= MmLLOFhp NVu4UoFOe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 NUjKTmlxOjN2OEm5PVk>
SK-HEP1 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zZVMyNTJyzszN MYW3Nog> MWfEUXNQ NVe2UVZsUUN3MP-8oFHPxE1? MUeyN|Q4QTF|Nh?=
786-0 NF7qOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXkO3EzOS1{MN88US=> NFfTTFk4Omh? MYfEUXNQ NXizXoRkUUN3MP-8oFHPxE1? M4ftVlI{PDd7MUO2
JVM2 NVj2TodLS3m2b4TvfIlkcXS7IHHzd4F6 NXP1WXVtOC5{LUKw{txO M2jiRlczcA>? MXvEUXNQ NInGUWFKSzVyPUCuPe69VQ>? M1TubVI{OjN6NkO5
EHEB MlXyR5l1d3SxeHnjbZR6KGG|c3H5 MU[wMlIuOjEQvF2= NX7OcmF2PzKq NXnjXmRnTE2VTx?= NFfNZoNKSzVyPUCuO:69VQ>? NXjFRoJ5OjN{M{i2N|k>
MEC2 M2HOdWN6fG:2b4jpZ4l1gSCjc4PhfS=> NEPzdpYxNjJvMkFOwG0> MmDCO|Jp M1zORmROW09? M1HP[2lEPTB;MD63{txO M4nmSVI{OjN6NkO5
primary B-CLL lymphocytes M1fydGFxd3C2b4Ppd{BCe3OjeR?= NHPwOopKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n MUSyOIg> MmizSG1UVw>? MVXJR|Ux97zeM988UUBnd3JiYXzsJJBifGmnboTz NEC2TWkzOzJ|OE[zPS=>
primary B-CLL lymphocytes NFnIfm1McW6jc3WgRZN{[Xl? NXLYdI9nUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= MVSyOIg> MkTPbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NGnaSmgzOzJ|OE[zPS=>
human NSCLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfFOpMxNjVvMt88US=> NETo[Yw4Omh? MmHkTWM2OD1zzszN NIjQUZYzOjd6MUO5Ny=>
human NSCLC M2r2SmtqdmG|ZTDBd5NigQ>? NF7oO48y|ryP MUiyOIg> MU\pcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62 NXmzZmlCOjJ5OEGzPVM>
Y1 cell line MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiwMlHPxE1xMd88US=> M2rJTVI1cA>? NWf0VGl2TE2VTx?= NVz5W|F5cW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= NX:0W|NpOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 M4PZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKT206T0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= NFnobIc4Omh? MorVS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? MUSyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 NHnCSpZMcW6jc3WgRZN{[Xl? MlrLTWM2OD1zMUVCtVNvVQ>? NFfDOVk4Omh? MVLJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| M{nrZVIzPjV|OU[3
MCF7-myr-Akt NEi0NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? Moj4O|Jp MVvHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M2DNSVIzPjV|OU[3
colon cancer cell lines M3O4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMVEx|ryP NITjT244Omh? NX3UWpRZTE2VTx?= M3LSd2lEPTB;Md88US=> MlvWNlI2PDN6NUe=
gastric cancer cell lines NE\wPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3DSYoxNTFyzszN MVq3Nog> MWPEUXNQ MlezTWM2OD1{LUZOwG0> MXeyNlU1Ozh3Nx?=
HCT-116/HT-29/MKN-45 MWPBdI9xfG:|aYOgRZN{[Xl? M4ryNlLPxE1? M2PmdFQ5cA>? NXLXXnIze2irZoSgbY4hTzJicHjhd4U> NETm[GozOjV2M{i1Oy=>
HT-29 and HCT-116 NX[yN|Y2S2G|cHHz[UBie3OjeR?= MonrOe69VQ>? M1Lo[|I1cA>? NXSwOWlEcW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5 MYCyNlU1Ozh3Nx?=
MM cell lines M37HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3wNVDPxE1? NUPreFd7OjSq MmXySG1UVw>? NVexOIY6UUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn NG\2bXUzOjJyN{S4OS=>
ARP-1 MnLpRZBweHSxc3nzJGF{e2G7 NITVeoUyOM7:TR?= NGHmeoMzPGh? MWDEUXNQ NFe5cIRqdmS3Y3XzJG1OKGOnbHygZZBweHSxc3nzJJRpem:3Z3igZ4F{eGG|ZTDhZ5RqfmG2aX;u NXvQclRzOjJ{MEe0PFU>
SNU-601 NYnJTlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj1O|Jp M2nHd2ROW09? MkexTWM2OD1yLkixOuKyOC5yNkROwG0> NF7JSXczOjF3OUixOC=>
SNU-1 NUDEUoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrNm4yPzKq NULUZo02TE2VTx?= M4m5TWlEPTB;MT6wPFLDuTBwMEK4{txO MWqyNlE2QThzNB?=
SNU-668 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3Nog> NWPnSmJrTE2VTx?= Mnq2TWM2OD1zLkW3PeKyOC5yN{VOwG0> NUX1VYtHOjJzNUm4NVQ>
AGS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\4fGQxPzKq NYnRNpRnTE2VTx?= Mly0TWM2OD1zLkexOOKyOC5zMUhOwG0> NV7odFhYOjJzNUm4NVQ>
SNU-216 NYD4eWdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5O|czcA>? MmDUSG1UVw>? NI\lXpNKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? M{SxWlIzOTV7OEG0
SNU-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\6V444Omh? M3fJNGROW09? MlLXTWM2OD1zLkO1NeKyOC5yOUJOwG0> MmLCNlIyPTl6MUS=
SNU-638 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjZRVU4Omh? M2faNWROW09? NInRXFdKSzVyPUKuNlgzyrFyLkC1N:69VQ>? NWXjO2dROjJzNUm4NVQ>
SNU-16 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaO|Jp MoG2SG1UVw>? M2DaOWlEPTB;MT61O|PDuTBwMECx{txO NIDhR5ozOjF3OUixOC=>
SNU-484 M{nsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XN[|czcA>? MVTEUXNQ Mk[3TWM2OD1zLkeyPOKyOC5yNEZOwG0> MnnZNlIyPTl6MUS=
SNU-620 M1Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyR|Q4Omh? NUnyfXhtTE2VTx?= M2j6[GlEPTB;Mj65N|nDuTBwMECx{txO MWmyNlE2QThzNB?=
SNU-719 M{HKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3Nog> NVuwWHViTE2VTx?= MW\JR|UxRTNwMEO3xtExNjB|Mt88US=> NGDHRYwzOjF3OUixOC=>
glioma cell lines MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW4O|Jp MUTJR|UxRTFvMt88US=> M4fyelIzODZ3MEiw
U87 NFi0PWhCeG:ydH;zbZMhSXO|YYm= MoLKNu69VQ>? NIrQTYM4Omh? MWnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?= M33ENlIzODZ3MEiw

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID